Recent Updates
Recently added Catalysts

Endometrial Cancer: two biotech companies racing to a treatment

OncologyConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$2.1Buniverse median $1.20B
Allocated capital$921M$4.2B competing
Phase 3 or filed01 mid, 1 early
Pure plays1this indication only
Capital rank156/299crowding rank 93

Endometrial Cancer is a two-horse race: Iovance Biotherapeutics (IOVA, $3.9B) against Whitehawk Therapeutics (WHWK, $264M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $921M of allocated capital sits on the pair.

IOVA alone accounts for 94% of the $4.2B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$921M of allocated capital sits in Endometrial Cancer, 156th of 299 indications, and 1 of the 2 companies are pure plays that trade on this indication alone.

Companies developing drugs for Endometrial Cancer 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
IOVAIovance BiotherapeuticsLifileucelPhase 21$3.9BNo6 23 Oct 2026
WHWKWhitehawk TherapeuticsHWK-007Phase 11$264MYes1 30 Jun 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile. IOVA holds 94% of the $4.2B competing in this indication.

Why Endometrial Cancer is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Endometrial Cancer has 2 competitors and a median of $2.1B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Advanced Solid Tumors With FGFR1 Amplification1 company · $967M · median $1.9BUncontestedCutaneous Squamous Cell Carcinoma2 companies · $978M · median $2.6BConcentrated betCervical Cancer1 company · $848M · median $2.5BUncontestedDiffuse Large B-Cell Lymphoma3 companies · $834M · median $351MOrphan cornerCancer Pain1 company · $798M · median $4.0BUncontestedAdvanced EGFR Mutant Non-Small Cell Lung Cancer1 company · $794M · median $794MUncontestedGlioma1 company · $792M · median $2.4BUncontestedMetastatic Head and Neck Squamous Cell Carcinoma1 company · $772M · median $1.5BUncontested

Endometrial Cancer pipeline questions

Which biotech companies are developing drugs for Endometrial Cancer?

Iovance Biotherapeutics (IOVA, Lifileucel, Phase 2); Whitehawk Therapeutics (WHWK, HWK-007, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Endometrial Cancer.

How advanced is the Endometrial Cancer pipeline?

Of the 2 clinical-stage programmes in Endometrial Cancer, 0 are in Phase 3 or filed, 1 is in mid-stage development and 1 is in early-stage development.

Which company leads the Endometrial Cancer field?

IOVA is the largest developer in Endometrial Cancer, holding 94% of the $4.2B of market capitalisation competing in the indication. The median competitor is worth $2.1B.

When is the next Endometrial Cancer catalyst?

The next dated catalyst in Endometrial Cancer is IOVA on 23 Oct 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map